Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Total Current Liabilities for 4 consecutive years, with $132.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 54.03% to $132.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132.0 million through Dec 2025, up 54.03% year-over-year, with the annual reading at $132.0 million for FY2025, 54.03% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $132.0 million at Phathom Pharmaceuticals, up from $93.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $132.0 million in Q4 2025, with the low at $11.4 million in Q1 2022.
  • Average Total Current Liabilities over 4 years is $50.8 million, with a median of $41.1 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities increased 2.23% in 2023, then soared 200.9% in 2024.
  • Over 4 years, Total Current Liabilities stood at $26.2 million in 2022, then surged by 47.81% to $38.8 million in 2023, then surged by 121.06% to $85.7 million in 2024, then skyrocketed by 54.03% to $132.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $132.0 million, $93.1 million, and $91.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.